CORCEPT PUBLISHES RESULTS OF PSYCHOTIC DEPRESSION STUDY

Corcept Therapeutics announced that an article describing the results of its Phase II clinical trial is available to the public in the Journal of Biological Psychiatry. The results of this study demonstrated with statistical significance that more patients treated with Corlux achieved a rapid and sustained reduction of the psychotic features of psychotic major depression than did patients treated with placebo.

The trial was a multicenter, randomized, placebo controlled study that evaluated 600 mg of the drug administered once daily over a period of seven days in patients with psychotic major depression. Patients were not allowed to receive any other antipsychotic or antidepressant medication for at least seven days prior to or during administration of the study drug. The study randomized 221 patients on a one-to-one basis to receive either drug or placebo.

The results of this study showed that patients who received Corlux were more likely than patients who received placebo to achieve a rapid and sustained reduction in psychosis as measured by a 30 percent reduction in the Brief Psychiatric Rating Scale (BPRS) at day seven sustained to day 28. Additionally, the study showed with statistical significance that patients receiving Corlux were more likely than patients receiving placebo to achieve a 50 percent reduction in the BPRS-positive symptom subscale (PSS) at day seven sustained to day 28.